Clinical Trials Browser

Phase 1/2 × Hematologic Neoplasms × zanubrutinib × Clear all

NCT06697184 2025-12-17

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms